T
TOLREMO therapeutics
Biotech & Life Sciences · Basel, Switzerland · Founded 2017
Focused on the discovery and development of small molecules to prevent resistance in cancer therapy MoreLess
TOLREMO Therapeutics is a biotechnology company focused on preventing resistance to cancer therapies. The company operates in the healthcare and pharmaceutical market, primarily serving patients with cancer and healthcare providers. TOLREMO's business model revolves around its proprietary drug discovery and development platform, which identifies novel drug resistance regulators and develops small molecule therapies to target these regulators. These therapies are designed to complement standard cancer treatments, aiming to improve response rates, extend survival times, and enhance the quality of life for patients. The company generates revenue through the development and commercialization of its proprietary therapies, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Keywords: cancer therapy, drug resistance, precision therapies, small molecule, drug discovery, biotechnology, healthcare, pharmaceutical, cancer patients, ETH Zurich spin-off.
Company overview
TOLREMO therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Basel, Switzerland
- Employees
- 16
- Open positions
- 1
- Dealroom signal
- 78.4
Valuation & funding
TOLREMO therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2023 | $31M | $125M | Pierre Fabre · BioMedVC | ↗ |
| SERIES A✓Equity / VC | Jun 2020 | $4.3M | $17M | Redalpine · ZKB - Zürcher Kantonalbank · BioMedVC · Altos Ventures | — |
| SUPPORT PROGRAM✓Other financing | Jan 2019 | $0 | — | EIT Health | — |
| SERIES A✓Equity / VC | Sep 2018 | $8.8M | $35M | Redalpine · ZKB - Zürcher Kantonalbank · Altos Ventures · BioMedVC | ↗ |
| EARLY VC✓Equity / VC | Sep 2017 | $2.3M | $9.2M | ZKB - Zürcher Kantonalbank | ↗ |
| SPINOUT✓Other financing | Jan 2017 | ETH Zurich | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $488K | 0% | 16 |
| 2025 | $488K | 0% | 15 |
| 2024 | $488K | 0% | 14 |
| 2023 | $488K | 0% | 9 |
| 2022 | $488K | 0% | 16 |
| 2021 | $488K | 0% | 15 |
| 2020 | $488K | — | 15 |
Growth signals
TOLREMO therapeutics website traffic
Latest recorded traffic for TOLREMO therapeutics is 2.1K monthly website visits, up 150% over the last three months. TOLREMO therapeutics's team grew 6.7% over the past year.
Comparisons
TOLREMO therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
TOLREMO therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where TOLREMO therapeutics has talent and traffic
team presence
In the news
Latest news about TOLREMO therapeutics
Recent press, funding announcements, and product moves mentioning TOLREMO therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about TOLREMO therapeutics
An AI-synthesized read of the highest-engagement posts about TOLREMO therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TOLREMO therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.